Calypso Biotech is an innovative leader in biopharmaceuticals, established in 2013 in Geneva, Switzerland. The company emerged from Merck Serono, a global authority in autoimmune diseases and biologics. Backed by a 2.5 million euro seed fund managed by MS Ventures, Calypso Biotech is known for its skilled team and strategic networks. The company operates as a semi-virtual organization and aims to provide substantial value for its investors through a portfolio of distinctive proprietary antibody candidates.
Recently, Calypso Biotech secured a significant €8.00M Series A investment on 09 September 2021. The investment came from a group of prominent investors including Gilde Healthcare, Fountain Healthcare Partners, MERL Ventures Fund, Inkef, and Johnson & Johnson Innovation – JJDC. With a seasoned management team and extensive expertise in drug development, Calypso Biotech is well-positioned to make a strong impact in the biotechnology and pharmaceutical industries.
